Can-Fite Biopharma Ltd (AMEX:CANF) is reporting third quarter earnings results on Monday 30th November 2020, before market open.
The consensus estimates from Thomson Reuters are loss of $ 0.24 per share.
For the full year, analysts predict revenues of $ 0.90 million, while looking forward to loss of $ 2.92 per share.
Previous Quarter Performance
Can-Fite Biopharma Ltd unfold loss for the second quarter of $ 0.01 per share, from the revenue of $ 0.20 million. The quarterly revenues down 48.72 percent compared with the same quarter last year. The consensus estimates are loss of $ 0.33 per share from $ 0.25 million in revenue. The bottom line results beat street analysts by $ 0.32 or 96.97 percent, at the same time, top line results fell short of analysts by $ 0.05 million or 20 percent.
Shares of Can-Fite Biopharma Ltd traded up $ 0.06 or 3.30 percent on Friday, reaching $ 1.88 with volume of 636.60 thousand shares. Can-Fite Biopharma Ltd has traded high as $ 1.92 and has cracked $ 1.79 on the downward trend
According to the previous trading day, closing price of $ 1.88, representing a 68.52 % increase from the 52 week low of $ 1.08 and a 63.23 % decrease over the 52 week high of $ 4.95.
The company has a market capital of $ 28.81 million and is part of the Healthcare sector and Biotechnology industry.
Can-Fite Biopharma Ltd will be hosting a conference call at 9:15 AM eastern time on 30th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.canfite.co.il
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases. The companys lead drug candidate is CF101 (Piclidenoson), which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis. It also develops CF102 (Namodenoson) that is in Phase II clinical trials for the treatment of liver cancer and non-alcoholic fatty liver diseases, as well as for hepatocellular carcinoma and hepatitis C virus diseases; and CF602, which is in pre-clinical trial for the treatment of sexual dysfunction.